17 completed, 5 terminated, 4 not yet recruiting, 4 recruiting. 37 Phase 2, 4 Phase 1, 1 Phase 3.
Follow Neuroma: new trials by email Literature Review of Neuroma trials Research Report on Neuroma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Selumetinib for NF2-Related Schwannomatosis Selumetinib - Neurofibromatosis Type 2, NF2 | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 20 | 2026-12-01 | 2026-10-28 |
| Luvometinib in Combination With Serplulimab for NF2-Related Tumors Luvometinib, Serplulimab - NF2-related Schwannomatosis, NF2 | Phase 1 / Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 30 | 2026-07-31 | 2026-07-16 |
| Platform Research for Innovative Medicines in NF2-SWN (PRIME-NF2) Selumetinib 25mg/m2, Luvometinib, Serplulimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Not yet recruiting | Beijing Tiantan Hospital | 200 | 2026-07-18 | 2026-07-20 |
| Study to Determine Optimal Dose, Evaluate the Efficacy and Safety of PRG-N-01 in Patients With Neurofibromatosis Type II Trineumin - Neurofibromatosis Type II, NF2 | Phase 1 / Phase 2 | Not yet recruiting | PRG Science & Technology Co., Ltd. | 25 | 2026-07-01 | 2026-01-23 |
| Pain Outcomes After Digital Amputation Using Tulavi Allay™ Nerve Cap Tulavi allay Nerve Cap - Neuroma, Neuropathic Pain | Phase 2 | Recruiting | Massachusetts General Hospital | 20 | 2025-09-20 | 2026-04-17 |
| Anti-VEGF Gene Therapy Trial for Vestibular Schwannoma AAVAnc80-antiVEGF via Akouos Delivery Device - Vestibular Schwannoma | Phase 1 / Phase 2 | Recruiting | Eli Lilly and Company | 27 | 2025-01-17 | 2026-11-04 |
| Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent RVP-001 - Central Nervous System (CNS) Lesions, Brain Metastases | Phase 2 | Completed | Reveal Pharmaceuticals Inc. | 18 | 2024-08-15 | 2025-12-26 |
| Screening Trial for Pain Relief in Schwannomatosis (STARFISH) Siltuximab, Erenumab-Aooe, Siltuximab Matching Placebo - Schwannomatosis, Schwannomas | Phase 2 | Recruiting | Massachusetts General Hospital | 40 | 2023-08-31 | 2026-07-24 |
| Doxycycline in Cutaneous Schwannoma (NF2) Doxycycline Injection [Doxy] - Neurofibromatosis Type 2 | Phase 1 / Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 19 | 2022-09-19 | 2026-10-16 |
| Efficacy and Safety of REC-2282 in Patients With Progressive Neurofibromatosis Type 2 (NF2) Mutated Meningiomas REC-2282, Placebo - Neurofibromatosis Type 2 | Phase 2 / Phase 3 | Terminated | Recursion Pharmaceuticals Inc. | 25 | 2022-06-20 | 2026-08-17 |
| Microscopic Fluorescence-guided Vestibular Schwannoma Resection Using Fluorescein Sodium and YELLOW 560 Fluorescein Sodium, YELLOW560 filter - Vestibular Schwannoma | Phase 2 | Completed | Mayo Clinic | 12 | 2021-10-06 | 2023-08-01 |
| Fluorescence Detection of Adult Primary Central Nervous System Tumors With Tozuleristide and the Canvas System tozuleristide, Canvas imaging system, Surgical resection of tumor - Central Nervous System Tumor | Phase 2 | Completed | John Yu | 50 | 2021-09-30 | 2026-07-10 |
| Nimodipine in Vestibular Schwanommas NiMODipine Injectable Solution, Placebo - Vestibular Schwannoma | Phase 2 | Unknown | Medical University of Vienna | 30 | 2021-05-04 | 2023-10-19 |
| Innovative Trial for Understanding the Impact of Targeted Therapies in NF2-Related Schwannomatosis (INTUITT-NF2) Brigatinib, Neratinib, Retifanlimab - Neurofibromatosis Type 2, Vestibular Schwannoma | Phase 2 | Recruiting | Scott R. Plotkin, MD, PhD | 109 | 2020-06-20 | 2026-11-12 |
| Phase 2 Study of Tanezumab in Subjects With Moderate to Severe Pain Due to Schwannomatosis Tanezumab, Placebo - Schwannomatosis, Pain | Phase 2 | Unknown | Massachusetts General Hospital | 9 | 2020-04-30 | 2024-03-13 |
| Phase 2 Clinical Trial of Crizotinib for Children and Adults With Neurofibromatosis Type 2 and Progressive Vestibular Schwannomas Crizotinib - Neurofibromatosis 2, Progressive Vestibular Schwannoma (VS) | Phase 2 | Completed | University of Alabama at Birmingham | 12 | 2020-02-18 | 2026-03-13 |
| Study of Aspirin in Patients With Vestibular Schwannoma Aspirin, Placebo - Vestibular Schwannoma, Acoustic Neuroma | Phase 2 | Active not recruiting | Massachusetts Eye and Ear Infirmary | 97 | 2018-03-01 | 2026-10-16 |
| RGD PET/MRI in Sporadic Vestibular Schwannoma One injection of 68Ga-NODAGA-E[c(RGDyK)]2 - Acoustic Neuroma | Phase 2 | Unknown | Copenhagen University Hospital, Rigshospitalet | 40 | 2018-01-02 | 2018-01-10 |
| Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors Selumetinib - Neurofibromatosis 2, Vestibular Schwannoma | Phase 2 | Terminated | Children's Hospital Medical Center, Cincinnati | 10 | 2017-05-08 | 2025-04-22 |
| AZD2014 In NF2 Patients With Progressive or Symptomatic Meningiomas AZD2014 - Neurofibromatosis 2, Meningioma | Phase 2 | Completed | Massachusetts General Hospital | 18 | 2016-08-31 | 2022-06-13 |
Showing 20 of 37. Sign in to see all of them.
Neurofibromatosis 2 (24) · Neuroma, Acoustic (22) · Meningioma (11) · Ependymoma (7) · Neurilemmoma (5) · Brain Neoplasms (4) · Central Nervous System Neoplasms (4) · Glioma (3) · Neurofibromatoses (3) · Pain (3) · Chronic Pain (2) · Hearing Loss (2) · Neurofibroma (2) · Neurofibromatosis 1 (2)
Neoplasms by Histologic Type (37) · Neoplasms, Nerve Tissue (37) · Nerve Sheath Neoplasms (37) · Neoplasms (36) · Nervous System Diseases (35) · Neuroectodermal Tumors (34) · Neuroendocrine Tumors (34) · Neoplasms, Germ Cell and Embryonal (33) · Cranial Nerve Diseases (31) · Cranial Nerve Neoplasms (31) · Ear Diseases (31) · Otorhinolaryngologic Neoplasms (31) · Retrocochlear Diseases (31) · Otorhinolaryngologic Diseases (30)
Bevacizumab (4) · AZD 6244 (3) · Everolimus (3) · Aspirin (1) · Axitinib (1) · Botulinum Toxins, Type A (1) · Crizotinib (1) · Doxycycline (1) · Endostatins (1) · Fluorescein (1) · Fluoresceins (1) · HDAC-42 (1) · Lapatinib (1) · Losartan (1) · Mn-PyC3A (1)
Massachusetts General Hospital (5) · Beijing Tiantan Hospital (4) · NYU Langone Health (3) · Massachusetts Eye and Ear Infirmary (2) · University of Alabama at Birmingham (2) · AlgoRx Pharmaceuticals (1) · Assistance Publique - Hôpitaux de Paris (1) · Burzynski Research Institute (1) · Children's Hospital Medical Center, Cincinnati (1) · Copenhagen University Hospital, Rigshospitalet (1) · Eli Lilly and Company (1) · FDA Office of Orphan Products Development (1) · John Yu (1) · Jonsson Comprehensive Cancer Center (1) · Li Peng (1)
United States (27) · China (5) · Austria (1) · Denmark (1) · France (1) · United Kingdom (1)
Matthias A Karajannis, MD, MS (3) · Scott Plotkin, MD (3) · D. Bradley Welling, MD, PhD (2) · Fu Zhao (2) · Pinan Liu (2) · Aaron Tward, MD (1) · Dorian Hirschmann, MD (1) · Eric Diamond, D.P.M. (1) · Girish Dhall, MD (1) · Helen A. Shih, MD (1) · Hjalte C.R. Sass, MD, Ph.d.-Fellow (1) · Jaishri Blakeley (1) · Jay Barth, MD (1) · John Yu, MD (1) · Karl Roessler, MD (1)
PMID 26976425, PMID 35229827, PMID 36038003, PMID 36240730, PMID 36798353, PMID 38372904, PMID 38904277, PMID 41530428, PMID 42788739
2017 (1), P30CA006973 (1), R44CA261240 (1)